Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new facility names and locations related to drug safety and information, specifically highlighting the availability of Efgartigimod Alfa in various cities across Belgium and Poland, while removing previous references to Sjögren syndrome and related topics.SummaryDifference5%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.